40119-34-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-2-p-tolylpropanenitrile is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its high reactivity allows for the creation of a wide range of medicinal agents, contributing to the development of new treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Methyl-2-p-tolylpropanenitrile is utilized as a precursor in the production of pesticides and other agricultural chemicals. Its role in synthesizing these compounds helps increase crop yields and protect plants from pests and diseases.
Used in Specialty Chemicals Industry:
2-Methyl-2-p-tolylpropanenitrile is employed as a building block in the synthesis of specialty chemicals, which are used in a variety of applications, such as coatings, adhesives, and fragrances. Its versatility in organic synthesis enables the creation of unique and high-performance chemical products.
Used as a Stabilizer in Rubber and Plastics Manufacturing:
P2-MN is used as a stabilizer in the production of rubber and plastics to enhance their durability and resistance to degradation. This contributes to the longevity and performance of these materials in various applications, from automotive parts to consumer products.

Upstream product

• 2947-61-7 (4-methylphenyl)acetonitrile 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 78-82-0 Isobutyronitrile 
• 1195-32-0 1-methyl-4-isopropenylbenzene 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 75920-47-7 2-methyl-2-p-tolyl-propionic acid amide 
• 20430-18-6 2-methyl-2-(p-tolyl)propanoic acid 
• 32454-12-9 2-methyl-2-(4-methylphenyl)propionaldehyde 
• 19884-69-6 2,3-Dimethyl-3-(4-methyl-phenyl)-2-chlor-butan 
• 32454-24-3 2-methyl-2-p-tolyl-propionic acid ethyl ester 
• 1201645-56-8 N-(5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridine-3-yl)benzenesulfonamide 
• 1201645-49-9 N-(3-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)phenyl)benzamide 
• 1201645-42-2 2-(4-(8-(9H-carbazol-2-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201644-55-4 tert-butyl 5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-ylcarbamate 
• 1201645-15-9 2-(4-((6-(dibenzo[b,d]furan-3-yl)-3-nitroquinolin-4-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1286764-90-6 C₂₉H₂₂N₆O 
• 1201645-16-0 2-(4-((6-(dibenzo[b,d]furan-3-yl)-3-aminoquinolin-4-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1201645-64-8 2-(4-(3-acetyl-8-(4-methylpiperazin-1-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201644-97-4 2-(4-(3-acetyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Synthesis of Tertiary Benzylic Nitriles via Nickel-Catalyzed Markovnikov Hydrocyanation of α-Substituted Styrenes

The Markovnikov hydrocyanation of α-substituted styrenes enables the synthesis of tertiary benzylic nitriles under nickel catalysis. The Lewis-acid-free transformation features an unprecedented functional groups tolerance, including the-OH and-NH2 groups. A broad range of tertiary benzylic nitriles were obtained in good to excellent yields. In addition, an asymmetric version of this reaction was preliminarily investigated.

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

VEGFR-2 inhibitor and preparation method thereof

The invention provides a compound I used as a VEGFR-2 inhibitor, a preparation method thereof, and an application of the compound I in the preparation of medicines for treating persistent vasculature induced diseases.

Synthesis and biologic activity of aryloxyaminopropanoles based on substituted p-tolylalkylamines

Reaction of 2,2-dimethyl-2-(p-tolyl)ethyl-, 1-p-tolylcyclopenthylmethyl- and 4-(p-tolyl)tetrahydro-2H-pyran-4-ylmethylamines with phenoxymethyloxiranes substituted in the aromatic ring afforded new aryloxypropanolamines, some of which show moderate adrenoblocking activity.

Synthesis of indolines by copper-mediated intramolecular aromatic C-H amination

A Cu(OAc)2-mediated intramolecular aromatic C-H amination proceeds with the aid of a picolinamide-type bidentate coordination group to deliver the corresponding indolines in good yields. The reaction occurs smoothly even under noble-metal-free conditions, and in some cases the use of an MnO2 terminal oxidant renders the process catalytic in Cu. The mild oxidation aptitude of Cu(OAc)2 and/or MnO2 accommodates the formation of electron-rich thiophene-and indole-fused indoline analogues. The Cu-based system can provide an effective approach to various indolines of potent interest in pharmaceutical and medicinal chemistry.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF

Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.

A convenient ring formation of 3-aryl-2,2-dialkyl-2,3-dihydrobenzofurans from phenols and 2-aryl-2,2-dialkylacetaldehydes

A new and simple route for the preparation of 3-aryl-2,2-dialkyl-2,3- dihydrobenzofurans from phenols is described. In the presence of an acid catalyst phenols react with 2-aryl-2,2-dialkylacetaldehydes, prepared in good yield from 2-arylacetonitriles in 2 steps, to give 3-aryl-2,2-dialkyl-2,3- dihydrobenzofurans. Electron-donating substituents were required on the phenols in order to give 3-aryl-2,2-dialkyl-2,3-dihydrobenzofurans in good yield.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.